|[January 22, 2013]
New Jersey Lt. Governor Kim Guadagno to Address BioNJ 2013 Annual Meeting
TRENTON, N.J. --(Business Wire)--
BioNJ, the trade association for New Jersey's growing biotechnology
industry, will welcome New Jersey Lt. Governor Kim Guadagno to address
attendees at the association's 20th Annual Meeting on
Thursday, February 7.
BioNJ's signature event, the 2013 Annual Dinner Meeting, Awards Program
and Networking Event will be held at the Hilton East Brunswick in East
Brunswick, NJ beginning at 5:30 p.m. Highlights also include a unique
fireside chat, Biotech in New Jersey…The Next 20 Years, which
will feature industry, financial and academic thought leaders, and the
presentation of the Dr. Sol J. Barer Award for Vision, Innovation and
Leadership to Dr. Francois Nader, President and CEO of NPS
Debbie Hart, President and CEO of BioNJ, said the Lt. Governor's
appearance reflects State Government's long-term support of the
biotechnology industry, which has grown from 80 companies in 1998 to
more than 350 today.
"One of the key factors in the industry's growth has been the support of
our Governors and State Legislators who have developed and supported
innovative policies and incentive programs that have nurtured the
industry over the years and the Governor Christie Administration is a
standout in that regard," said Debbie Hart. "We are honored that Lt.
Governor Kim Guadagno can be with us this year. Ardent supporters of
biotech, Governor Chris Christie and Lt. Governor Guadagno are committed
to making New Jersey one of the most biotech friendly states in the
About BioNJ's 20th Annual Meeting
Growing i prominence with each year, the Annual Meeting brings together
executives of biotechnology and pharmaceutical companies, professional
service providers, government officials, academic leaders and others for
an evening of networking, business discussions and award presentations.
More than 700 people attended the 2012 meeting.
The Dr. Sol J. Barer Award for Vision, Innovation, and Leadership was
established by the BioNJ Board of Trustees in March 2008 in an effort to
recognize the outstanding research and business leaders who have made
and continue to make significant contributions to the growth of the
biosciences in New Jersey and around the world. The honoree is voted on
by the BioNJ Board of Trustees from a recommendation based on
nominations received by the Nominating Committee. The award is named for
and will be presented by Sol J. Barer, Ph.D., who founded the
biotechnology group at Celanese that was subsequently spun out to form
Celgene, one of the world's largest biotechnology companies.
The 2013 awardee, Dr. Nader, has served as President, CEO and a member
of the Board of Directors of NPS Pharmaceuticals since 2008. During his
tenure, Dr. Nader transformed NPS into a leading biotechnology company
focused on treatments for patients with rare disorders in
gastroenterology and endocrinology. NPS' lead product, Gattex for short
bowel syndrome, was approved in the United States and Europe in 2012.
NPS is also developing Natpara® for a rare endocrine disorder,
hypoparathyroidism, and plans to file its Biologic License Application
seeking U.S. marketing approval in mid-2013.
The fireside chat, Biotech in New Jersey…the Next 20 Years, will
feature: Dr. Robert L. Barchi, President of Rutgers, The State
University; James C. Greenwood, President and CEO of the Biotechnology
Industry Organization (BIO); Robert J. Hugin, Chairman and CEO of
Celgene Corporation; Mary C. Tanner, Senior Managing Director of Burrill
and Company and Burrill Securities, and Dr. Jesse I. Treu, Partner,
Domain Associates. The Wall Street Journal staff writer Jonathan
Rockoff will serve as moderator.
BioNJ is singularly focused on advancing the growth and prosperity of
New Jersey's biotechnology cluster through advocacy initiatives directed
at State and federal public policy issues and networking and educational
programs that bring the community together. Founded in 1994 by New
Jersey industry CEOs, the 300-member organization serves as the voice of
biotechnology companies located in New Jersey, seeks to promote their
economic growth and development and works to encourage new and
established companies from around the world to locate to New Jersey.
BioNJ represents companies engaged in biopharmaceutical, biomedical,
bioagricultural and bioremedial endeavors.
To learn more about BioNJ and the 2013 Annual Dinner Meeting, please
[ Back To TMCnet.com's Homepage ]